Hermansky-Pudlak Syndrome Type 1 Causes Impaired Anti-microbial Immunity and Inflammation Due to Dysregulated Immunometabolism
Overview
Authors
Affiliations
Hermansky-Pudlak syndrome (HPS) types 1 and 4 are caused by defective vesicle trafficking. The mechanism for Crohn's disease-like inflammation, lung fibrosis, and macrophage lipid accumulation in these patients remains enigmatic. The aim of this study is to understand the cellular basis of inflammation in HPS-1. We performed mass cytometry, proteomic and transcriptomic analyses to investigate peripheral blood cells and serum of HPS-1 patients. Using spatial transcriptomics, granuloma-associated signatures in the tissue of an HPS-1 patient with granulomatous colitis were dissected. In vitro studies were conducted to investigate anti-microbial responses of HPS-1 patient macrophages and cell lines. Monocytes of HPS-1 patients exhibit an inflammatory phenotype associated with dysregulated TNF, IL-1α, OSM in serum, and monocyte-derived macrophages. Inflammatory macrophages accumulate in the intestine and granuloma-associated macrophages in HPS-1 show transcriptional signatures suggestive of a lipid storage and metabolic defect. We show that HPS1 deficiency leads to an altered metabolic program and Rab32-dependent amplified mTOR signaling, facilitated by the accumulation of mTOR on lysosomes. This pathogenic mechanism translates into aberrant bacterial clearance, which can be rescued with mTORC1 inhibition. Rab32-mediated mTOR signaling acts as an immuno-metabolic checkpoint, adding to the evidence that defective bioenergetics can drive hampered anti-microbial activity and contribute to inflammation.
Pathogenesis and Therapy of Hermansky-Pudlak Syndrome (HPS)-Associated Pulmonary Fibrosis.
Hu X, Wei Z, Wu Y, Zhao M, Zhou L, Lin Q Int J Mol Sci. 2024; 25(20).
PMID: 39457053 PMC: 11508683. DOI: 10.3390/ijms252011270.
Syed F, Ballew O, Lee C, Rana J, Krishnan P, Castela A bioRxiv. 2024; .
PMID: 38766166 PMC: 11100605. DOI: 10.1101/2024.03.20.585925.
Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards.
Uhlig H, Booth C, Cho J, Dubinsky M, Griffiths A, Grimbacher B Nat Rev Gastroenterol Hepatol. 2023; 20(12):810-828.
PMID: 37789059 DOI: 10.1038/s41575-023-00838-4.
Modulation of innate immunity in airway epithelium for host-directed therapy.
Myszor I, Gudmundsson G Front Immunol. 2023; 14:1197908.
PMID: 37251385 PMC: 10213533. DOI: 10.3389/fimmu.2023.1197908.